Healthy ParticipantsNCT07267845
The Effect of α-GPC on Cognitive Function and Sports Performance
A study testing Alpha-Glycerophosphocholine（α-GPC） in people with Healthy Participants, run by Nanjing Nutrabuilding Bio-tech Co., Ltd. at 1 site in Ireland.
Trial summary
The goal of this clinical trial is to find out whether daily supplementation with Alpha-Glycerophosphocholine (α-GPC) can improve cognitive function and sports performance in healthy adults. It will also assess the safety and tolerability of α-GPC when taken over a 6-week period. Read more about this study
- Who is it for?
- Ages 25 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Participants
- What is being tested?
- Alpha-Glycerophosphocholine（α-GPC）
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteIreland
- Study dates
- 21 Oct 2025to 5 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be able to give written informed consent.
- Be in good health as determined by the investigator.
- Age between 25 and 55 years (inclusive).
- Body Mass Index of 18.5-32.0 kg/m2 (inclusive).
- Body weight of at least 54 kilograms.
- Muscle strengthening activities 2-3 time per week or participation in recreational or local level moderate intensity activity for at least 2 years.
Show all 9Show fewer
- Normotensive (resting systolic blood pressure <140 mm Hg and diastolic blood pressure < 90 mm Hg).
- Willing to duplicate their previous 24-hr diet, refrain from alcohol and caffeine for 24-hr prior to each visit, refrain from exercise 48-hr prior to each visit.
- Refrain from consuming beef liver, chicken liver, eggs, fish, wheat germ and soybeans, butter beans 24-hrs prior to Visit 2 and Visit 3.
Who cannot join
- Highly trained or competitive athletes.
- Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
- Female participants who are currently breastfeeding.
- Female participants who are planning to become pregnant during the study period.
- Female participants who test positive on a pregnancy test at screening or prior to first administration of the study product.
- Participants with history of drug and/or alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); alcohol/substance abuse disorder).
Show all 28Show fewer
- Caffeine intake of three or more cups of coffee or equivalent (>400 mg) per day.
- Current smokers or users of any nicotine products in the past 4-weeks.
- Has food allergies or other issues with foods that would preclude intake of the Study Products.
- Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.
- History of malignancy in the previous 5 years except for non-melanoma skin cancer.
- Diagnosed, uncontrolled psychiatric disorder.
- Hepatorenal, musculoskeletal, autoimmune, or neurologic disease.
- Prior gastrointestinal bypass surgery (excluding appendectomy).
- Gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism.
- Chronic inflammatory condition or disease.
- History of severe or chronic musculoskeletal pain or injury.
- History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS/IBD.
- Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.
- Use CNS stimulants or anxiety or ADHD medication.
- Use corticosteroids (oral, subcutaneous, intramuscular, or transdermal only).
- Use testosterone replacement therapy (ingestion, injection, or transdermal).
- Current or recent use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator.
- Use creatine, BCAA, HMB, betaine, beta-alanine, in the past 2 weeks.
- Use choline supplements (e.g. choline bitartrate, phosphatidylcholine, citicholine) in the past 4 weeks.
- Use omega-3, ginkgo biloba, ginseng, L-theanine, Lion's Mane, ashwagandha in the past 4 weeks.
- Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
- Participants may be participating in other clinical studies.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ireland1 site, 1 recruiting
- Recruiting
Atlantia Clinical Trials
Cork, County Cork, P56 W9X2
Nontokozo Yusuff, MBChC, nyusuff@atlantiatrials.com
About this study
Official title: A Randomised, Double-Blind, Placebo-Controlled Study on the Effects of Alpha-Glycerophosphocholine (α-GPC) on Cognitive Function and Sports Performance in Adults
The goal of this clinical trial is to find out whether daily supplementation with Alpha-Glycerophosphocholine (α-GPC) can improve cognitive function and sports performance in healthy adults. It will also assess the safety and tolerability of α-GPC when taken over a 6-week period.
The main questions this study aims to answer are:
Read more
Does taking α-GPC every day improve cognitive performance on tests such as the Stroop Test, Go/No-go Test, Sustained Attention to Response Task (SART), and Digit-Symbol Substitution Test (DSST)? Does α-GPC enhance upper and lower body sports performance? Does α-GPC positively affect perceived mood, energy, and motivation? Is α-GPC safe and well tolerated compared to a placebo? Researchers will compare α-GPC (350 mg per day) to a placebo (an inactive substance that looks the same) in a randomized, double-blind study. Neither the participants nor the researchers will know who receives α-GPC or the placebo.
Participants will:
Be randomly assigned to take either α-GPC or placebo capsules once daily for 6 weeks Attend 3 study visits over an 8-week period at Atlantia Clinical Trials in Cork, Ireland Complete cognitive and physical performance tests both acutely (shortly after a single dose) and after 6 weeks of daily use Have their vital signs, body weight, and any adverse events monitored throughout the study Record their diet and well-being during the study period This study will include 80 healthy adults aged 25-55 years who regularly engage in physical activity. The results will help determine whether α-GPC has benefits for brain function and physical performance, and whether it is safe for long-term use.
- Conditions
- Healthy Participants
- Being tested
- Alpha-Glycerophosphocholine（α-GPC）, Microcrystalline Cellulose (placebo)
- Keywords
- Alpha-Glycerophosphocholine, α-GPC, cognitive function, sports performance, Dietary Supplement, safety
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Alpha-Glycerophosphocholine（α-GPC）Dietary supplement
Participants will oral one capsule containing 350 mg of GeniusPure® (containing 315 mg of pure α-GPC) daily before breakfast for 6 weeks.
Microcrystalline Cellulose (placebo)Dietary supplement
Participants will oral one capsule containing 350 mg of microcrystalline cellulose (MCC) daily before breakfast for 6 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Dietary Supplement: 315 mg α-GPC | Experimental | Not described Receives: Dietary Supplement: Alpha-Glycerophosphocholine（α-GPC） |
| Placebo | Placebo comparator | Not described Receives: Dietary Supplement: Microcrystalline Cellulose (placebo) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cognitive Performance - Stroop Test-Stroop total score
Test the stroop total score change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Secondary outcomes (28)
Cognitive Performance - Stroop Test - Stroop accuracy (%)
Test the stroop accuracy (%) change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Stroop Test - Stroop time per score (s)
Test the stroop time per score (s) change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Number of Correct Symbols (N)
Test the Number of Correct Symbols (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Total Correct Score
Test the Total Correct Score change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Accuracy (%)
Test the Accuracy (%) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Time per Correct Response (s/item)
Test the Time per Correct Response (s/item) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Go/No-go Test - Correct responses (N)
Test the Go/No-Go - Correct responses (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Errors of omissions (%)
Test the Go/No-Go - Errors of omissions (%) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Errors of commission (%)
Test the Go/No-Go - Errors of commission (%) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Correct rejections (N)
Test the Go/No-Go - Correct rejections (N) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Mean response times (mins)
Test the Go/No-Go - Mean response times (mins) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Reaction time (mins)
Test the Reaction time (mins) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test- Reaction time variability (RTV)
Test the Reaction time variability (RTV) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive Performance - Sustained Attention to Response Task (SART) - Total Commission Errors (N)
Test total commission errors (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Sustained Attention to Response Task (SART) - Omission Errors (N)
Test omission errors (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time (Mean RT)
Test reaction time (Mean RT) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time Variability (RTV)
Test reaction time variability (RTV) change (Δ) from Day 1 to Day 42 effect in the α-GPC group compared to placebo on.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Upper Body Power - Average power (W)
The average power (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press.
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Upper Body Power - Peak power production (W)
The peak power production (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press.
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Upper Body Power - Peak Velocity (m/s)
The peak velocity (m/s) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press.
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Upper Body Power - Peak force production (N)
The peak force production (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to the Placebo group will be assessed by Ballistic Smith Machine Bench Press.
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Average power (W)
Test the average power (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo).
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Peak power production (W)
Test the peak power production (W) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo).
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Peak Velocity (m/s)
Test the peak Velocity (m/s) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo).
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Peak force production (N)
Test the peak force production (N) change (Δ) from Day 1 to Day 42 in the α-GPC group compared to placebo on Vertical Jump for Lower Body Power (Tendo).
Measured: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Perceived mood assessment
Perceived mood assessed using the Visual Analog Scale (VAS), a 0-100 scale where 0 indicates 'worst mood imaginable' and 100 indicates 'best mood imaginable.' Higher scores represent better perceived mood.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Perceived motivation assessment
Perceived motivation assessed using the Visual Analog Scale (VAS), with a range of 0-100 where 0 indicates 'no motivation' and 100 indicates 'maximum motivation.' Higher scores represent better perceived motivation.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Perceived energy assessment
Perceived energy assessed using the VAS, with a range of 0-100 where 0 indicates 'no energy' and 100 indicates 'maximum energy.' Higher scores represent better perceived energy.
Measured: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Dec 2025
- Study start21 Oct 2025
- Primary completion15 May 2026 (estimated)
- Study completion5 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Healthy ParticipantsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Nanjing Nutrabuilding Bio-tech Co., Ltd.
- Sponsor type
- University, hospital or other
- Collaborators
- Atlantia Food Clinical Trials
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07267845
- Sponsor's protocol ID
- NNB2025HCS-AFCRO-199
- Status last verified
- Dec 2025
- First submitted
- 14 Nov 2025
- Last updated
- 9 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024 Dec 9;16(23):4240. doi: 10.3390/nu16234240.
PubMed 39683633Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):331-5.
PubMed 1428296Yamashita S, Kawada N, Wang W, Susaki K, Takeda Y, Kimura M, Iwama Y, Miura Y, Sugano M, Matsuoka R. Effects of egg yolk choline intake on cognitive functions and plasma choline levels in healthy middle-aged and older Japanese: a randomized double-blinded placebo-controlled parallel-group study. Lipids Health Dis. 2023 Jun 20;22(1):75. doi: 10.1186/s12944-023-01844-w.
PubMed 37340479
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-Blind, Placebo-Controlled Study on the Effects of Alpha-Glycerophosphocholine (α-GPC) on Cognitive Function and Sports Performance in Adults
- ClinicalTrials.gov ID
- NCT07267845
- Acronym / sponsor ID
- NNB2025HCS-AFCRO-199
- Conditions
- Healthy Participants
- Keywords
- Alpha-Glycerophosphocholine, α-GPC, cognitive function, sports performance, Dietary Supplement, safety
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Nanjing Nutrabuilding Bio-tech Co., Ltd.University, hospital or other
- Collaborators
- Atlantia Food Clinical Trials
- Study start
- 21 Oct 2025 (actual)
- Primary completion
- 15 May 2026 (estimated)
- Study completion
- 5 Jul 2026 (estimated)
- First posted
- 5 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to find out whether daily supplementation with Alpha-Glycerophosphocholine (α-GPC) can improve cognitive function and sports performance in healthy adults. It will also assess the safety and tolerability of α-GPC when taken over a 6-week period.
The main questions this study aims to answer are:
Does taking α-GPC every day improve cognitive performance on tests such as the Stroop Test, Go/No-go Test, Sustained Attention to Response Task (SART), and Digit-Symbol Substitution Test (DSST)? Does α-GPC enhance upper and lower body sports performance? Does α-GPC positively affect perceived mood, energy, and motivation? Is α-GPC safe and well tolerated compared to a placebo? Researchers will compare α-GPC (350 mg per day) to a placebo (an inactive substance that looks the same) in a randomized, double-blind study. Neither the participants nor the researchers will know who receives α-GPC or the placebo.
Participants will:
Be randomly assigned to take either α-GPC or placebo capsules once daily for 6 weeks Attend 3 study visits over an 8-week period at Atlantia Clinical Trials in Cork, Ireland Complete cognitive and physical performance tests both acutely (shortly after a single dose) and after 6 weeks of daily use Have their vital signs, body weight, and any adverse events monitored throughout the study Record their diet and well-being during the study period This study will include 80 healthy adults aged 25-55 years who regularly engage in physical activity. The results will help determine whether α-GPC has benefits for brain function and physical performance, and whether it is safe for long-term use.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dietary Supplement: 315 mg α-GPC | Experimental | Dietary Supplement: Alpha-Glycerophosphocholine（α-GPC） |
| Placebo | Placebo comparator | Dietary Supplement: Microcrystalline Cellulose (placebo) |
Who may qualify
- Ages
- 25 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (9 listed)
- Be able to give written informed consent.
- Be in good health as determined by the investigator.
- Age between 25 and 55 years (inclusive).
- Body Mass Index of 18.5-32.0 kg/m2 (inclusive).
- Body weight of at least 54 kilograms.
Key exclusion criteria (28 listed)
- Highly trained or competitive athletes.
- Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
- Female participants who are currently breastfeeding.
- Female participants who are planning to become pregnant during the study period.
- Female participants who test positive on a pregnancy test at screening or prior to first administration of the study product.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Alpha-Glycerophosphocholine（α-GPC）Participants will oral one capsule containing 350 mg of GeniusPure® (containing 315 mg of pure α-GPC) daily before breakfast for 6 weeks. | Dietary supplement | Dietary Supplement: 315 mg α-GPC |
| Microcrystalline Cellulose (placebo)Participants will oral one capsule containing 350 mg of microcrystalline cellulose (MCC) daily before breakfast for 6 weeks. | Dietary supplement | Placebo |
Primary outcome
Cognitive Performance - Stroop Test-Stroop total score
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Test the stroop total score change (Δ) of from Day 1 to Day 42 in the α-GPC group compared to placebo on Stroop Test.
28 secondary outcomes
Cognitive Performance - Stroop Test - Stroop accuracy (%)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Stroop Test - Stroop time per score (s)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Number of Correct Symbols (N)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Total Correct Score
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Accuracy (%)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Digit-Symbol Substitution Test (DSST) - Time per Correct Response (s/item)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive performance - Go/No-go Test - Correct responses (N)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Errors of omissions (%)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Errors of commission (%)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Correct rejections (N)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Mean response times (mins)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test - Reaction time (mins)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive performance - Go/No-go Test- Reaction time variability (RTV)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Cognitive Performance - Sustained Attention to Response Task (SART) - Total Commission Errors (N)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Sustained Attention to Response Task (SART) - Omission Errors (N)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time (Mean RT)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Cognitive Performance - Sustained Attention to Response Task (SART) - Reaction Time Variability (RTV)
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）
Upper Body Power - Average power (W)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Upper Body Power - Peak power production (W)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Upper Body Power - Peak Velocity (m/s)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Upper Body Power - Peak force production (N)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Average power (W)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Peak power production (W)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Peak Velocity (m/s)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Lower Body Power - Peak force production (N)
Time frame: Assessed 90 minutes after ingestion of assigned test product during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Perceived mood assessment
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Perceived motivation assessment
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Perceived energy assessment
Time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2025.
- Results publication: PubMed 39683633Kerksick CM. Acute Alpha-Glycerylphosphorylcholine Supplementation Enhances Cognitive Performance in Healthy Men. Nutrients. 2024 Dec 9;16(23):4240. doi: 10.3390/nu16234240.
- Results publication: PubMed 1428296Gatti G, Barzaghi N, Acuto G, Abbiati G, Fossati T, Perucca E. A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. Int J Clin Pharmacol Ther Toxicol. 1992 Sep;30(9):331-5.
- Results publication: PubMed 37340479Yamashita S, Kawada N, Wang W, Susaki K, Takeda Y, Kimura M, Iwama Y, Miura Y, Sugano M, Matsuoka R. Effects of egg yolk choline intake on cognitive functions and plasma choline levels in healthy middle-aged and older Japanese: a randomized double-blinded placebo-controlled parallel-group study. Lipids Health Dis. 2023 Jun 20;22(1):75. doi: 10.1186/s12944-023-01844-w.
- Individual participant dataSharing planned: No
Related trials for Healthy Participants
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
RecruitingPhase 1
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Healthy Female Participants
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Alpha-Glycerophosphocholine（α-GPC） in people with Healthy Participants, run by Nanjing Nutrabuilding Bio-tech Co., Ltd. at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Nontokozo Yusuff, MBChC (+353 (0)21-430 7442, nyusuff@atlantiatrials.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cognitive Performance - Stroop Test-Stroop total score (time frame: Assessed 60 minutes after ingestion of assigned test product and approximately 3 hours after ingestion during baseline（visit 2, week 1, day1） and end of the study（visit 3, week 6, day42）). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07267845, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2025.